patients

Curia Sterile Drug Product Facility Named Massachusetts Manufacturer of the Year

ALBANY, N.Y., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization,…

2 weeks ago

Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational…

2 weeks ago

PSMAddition data show Novartis Pluvicto delays progression to end-stage prostate cancer

Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition…

2 weeks ago

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100…

2 weeks ago

Industry Leaders Join Ingenio Cares Mission to Redefine Access, Coordination, and Value in U.S. Healthcare

OAK BROOK, Ill., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Ingenio Care, Inc., an AI-driven digital health company, today announced the…

2 weeks ago

SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology

BOSTON and ROLLE, Switzerland, Oct. 16, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in AI-driven precision medicine, today announced…

2 weeks ago

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

October 17, 2025 16:05 ET  | Source: Jade Biosciences Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding…

2 weeks ago

Domp’s Program in NAION Selected for Landmark FDA Commissioners National Priority Voucher Program

One of just nine voucher recipients chosen and the only one in the eye space, the selection spotlights Dompé’s dedication…

3 weeks ago

Labaton Keller Sucharow LLP Files Securities Class Action Against Baxter International, Inc. and Certain of Its Executives

NEW YORK--(BUSINESS WIRE)--Labaton Keller Sucharow LLP (“Labaton”) has filed a securities class action lawsuit (the “Action”) on behalf of its…

3 weeks ago

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner’s National Priority Voucher Pilot Program

REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing…

3 weeks ago